Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan vs Standard Triple Therapy for H. pylori Eradication (VECTOR)
NCT06959368Phase 4Recruiting
- Sponsor
- Asian Institute of Gastroenterology
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vonoprazan in Helicobacter pylori infection (2 arms), sponsored by Asian Institute of Gastroenterology. Primary endpoint: Helicobacter pylori eradication rate at 1 year. Started Mar 2025; status: recruiting.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06959368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06959368.